Indications And Dose
Maintenance treatment of chronic obstructive pulmonary disease ▶BY INHALATION OF POWDER ▶Adult: 1 inhalation once daily
PDF page 285
Loading InternPractice…
Drug reference
Maintenance treatment of chronic obstructive pulmonary disease ▶BY INHALATION OF POWDER ▶Adult: 1 inhalation once daily
PDF page 285
Arrhythmias. cardiovascular disease. diabetes (risk of hyperglycaemia and ketoacidosis). hypertension. hyperthyroidism. hypokalaemia. susceptibility to QT- interval prolongation CAUTIONS, FURTHER INFORMATION ▶Hypokalaemia Potentially serious hypokalaemia may result from beta2 agonist therapy. Particular caution is required in severe asthma, because this effect may be potentiated by concomitant treatment with theophylline and its derivatives, corticosteroids, diuretics, and by hypoxia. Arrhythmias. cardiovascular disease. diabetes (risk of hyperglycaemia and ketoacidosis, especially with intravenous use). hypertension. hyperthyroidism. hypokalaemia. susceptibility to QT-interval prolongation CAUTIONS, FURTHER INFORMATION ▶Hypokalaemia Potentially serious hypokalaemia may result from beta2 agonist therapy. Particular caution is required in severe asthma, because this effect may be potentiated by concomitant treatment with theophylline and its derivatives, corticosteroids, diuretics, and by hypoxia.
PDF pages 285, 286
→Appendix 1: beta2 agonists. umeclidinium
PDF page 285
▶Common or very common Constipation. dry mouth. headache. oropharyngeal pain. sinusitis ▶Uncommon Arrhythmias. dysphonia. palpitations. taste altered. tremor ▶Rare or very rare Bronchospasm paradoxical. glaucoma. urinary disorders. vision blurred ▶Common or very common Arrhythmias. dizziness. headache. hypokalaemia (with high doses). nausea. palpitations. tremor ▶Uncommon Hyperglycaemia. myocardial ischaemia ▶Rare or very rare Bronchospasm paradoxical (sometimes severe)
PDF pages 285, 286
▶In severe asthma, plasma-potassium concentration should be monitored (risk of hypokalaemia). ▶In patients with diabetes, monitor blood glucose (risk of hyperglycaemia and ketoacidosis, especially when beta2 agonist given intravenously). ▶In severe asthma, plasma-potassium concentration should be monitored (risk of hypokalaemia). ▶In patients with diabetes, monitor blood glucose (risk of hyperglycaemia and ketoacidosis, especially when beta2 agonist given intravenously).
PDF pages 285, 286
Women planning to become pregnant should be counselled about the importance of taking their asthma medication regularly to maintain good control.
PDF page 286
There can be variation in the licensing of different medicines containing the same drug. Inhalation powder A ▶Umeclidinium with vilanterol (non-proprietary) Vilanterol (as Vilanterol trifenatate) 22 microgram per 1 dose, Umeclidinium bromide 65 microgram per 1 dose Umeclidinium bromide 65micrograms/dose / Vilanterol 22micrograms/dose dry powder inhaler | 30 dose P s DT = £32.50 ▶Anoro Ellipta (GlaxoSmithKline UK Ltd) A Vilanterol (as Vilanterol trifenatate) 22 microgram per 1 dose, Umeclidinium bromide 65 microgram per 1 dose Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler | 30 dose P £32.50 DT = £32.50 BETA2-ADRENOCEPTOR AGONISTS, SELECTIVE Beta-2- adrenoceptor agonists, f selective Respiratory system
PDF pages 285, 286
Patient or carers should be given advice on appropriate inhaler technique. ▶When used by inhalation The dose, the frequency, and the maximum number of inhalations in 24 hours of the beta2 agonist should be stated explicitly to the patient or their carer. The patient or their carer should be advised to seek medical advice when the prescribed dose of beta2 agonist fails to provide the usual degree of symptomatic relief because this usually indicates a worsening of the asthma and the patient may require a prophylactic drug. Patients or their carers should be advised to follow manufacturers’ instructions on the care and cleansing of inhaler devices. BETA2-ADRENOCEPTOR AGONISTS, SELECTIVE › LONG-ACTING eiiii F above
PDF pages 285, 286
1 inhalation once daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 285